Drug Repositioning for Refractory Benign Tumors of the Central Nervous System
International Journal of Molecular Sciences · 20.08.2023 · 24 (16) · 12997
DOI: 10.3390/ijms241612997 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.08.2023. Verfasst von Ryota Tamura. Beteiligte Einrichtung: Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Hauptthemen laut MEDLINE: Meningioma, Neurilemmoma, Pituitary Neoplasms, Meningeal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared with the process of de novo drug discovery. Although the number of publications related to DR has rapidly increased, most therapeutic approaches were reported for malignant tumors. Surgical resection represents the definitive treatment for benign tumors of the central nervous system (BTCNS). However, treatment options remain limited for surgery-, chemotherapy- and radiation-refractory BTCNS, as well as malignant tumors. Meningioma, pituitary neuroendocrine tumor (PitNET), and schwannoma are the most common BTCNS. The treatment strategy using DR may be applied for refractory BTCNS, such as Grade 2 meningiomas, neurofibromatosis type 2-related schwannomatosis, and PitNETs with cavernous sinus invasion. In the setting of BTCNS, stable disease can provide significant benefit to the patient. DR may provide a longer duration of survival without disease progression for patients with refractory BTCNS. This article reviews the utility of DR for refractory BTCNS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
ORCID-Profile: Ryota Tamura
Zitieren
APA
Tamura, R. (2023). Drug Repositioning for Refractory Benign Tumors of the Central Nervous System. International Journal of Molecular Sciences, 24(16), 12997. https://doi.org/10.3390/ijms241612997
Vancouver
Tamura R. Drug Repositioning for Refractory Benign Tumors of the Central Nervous System. International Journal of Molecular Sciences. 2023;24(16):12997. doi:10.3390/ijms241612997
BibTeX
@article{Tamura2023,
author = {Tamura, Ryota},
title = {Drug Repositioning for Refractory Benign Tumors of the Central Nervous System},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {16},
pages = {12997},
doi = {10.3390/ijms241612997}
}
EUVIMED